Tao Synergies Inc (TAOX)

$7.05 -0.60 (-7.84%)
Market Cap 26.89M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 221,143
Avg Vol 254,228
Day's Range N/A - N/A
Shares Out 3.49M
Stochastic %K 83%
Beta 1.89
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
TaoistTrader
TaoistTrader Oct. 9 at 5:56 PM
$TAOX giving back all them gains 🤔
0 · Reply
SnoopyPotter
SnoopyPotter Oct. 9 at 12:45 PM
$TAOX $TAO.X to $1,500? $TAOX could hit $36+ (base case)! With 42K+ $TAO.X staked. If $TAO.X reaches $3K, we’re talking about 10x potential from $7.75! Earnings Dec 3 for staking updates. What's your price target? #Bittensor #Crypto #BullRun Not advice, DYOR
0 · Reply
IldijanaMM
IldijanaMM Oct. 9 at 12:35 PM
$QCLS $TAO.X $TAOX How dose your all in play going JJ?
1 · Reply
JJBurch
JJBurch Oct. 9 at 10:38 AM
$QCLS just waiting on that ONE or and likely about $TAO.X ( $TAOX ) and this will join the 1000%+ club The best part of waiting is the ability to continue to accumulate more shares I thank god (my hard work in life) for the ability to do so. I’m so excited for this one it’s nearly ridiculous. Just absolutely SO EXCITED!! Let’s go @jaltucher LFG!!!
0 · Reply
SnoopyPotter
SnoopyPotter Oct. 8 at 8:21 PM
$TAOX Led by @jaltucher $TAOX acquired 29,899 $TAO.X tokens for $10M (~$334/token). Massive potential for 10x by EOY with $TAO.X halving in December. Oct 2: If you’re bullish on $TAO.X’s year-end targets, $TAOX is a must-watch. Halving catalysts are near!
1 · Reply
EndGame1
EndGame1 Oct. 8 at 1:12 PM
$TAOX Back to $8. $TAO is getting traction from many high profiles on twitter.
0 · Reply
EndGame1
EndGame1 Oct. 7 at 8:08 PM
$TAOX It was time for some profit taking. Think long term though for big reward.
0 · Reply
MelanieEllis
MelanieEllis Oct. 7 at 7:57 PM
$TAOX NXXT consolidation between 2.85 and 2.95 into the close looks like fuel into tomorrow break 2.95 and vroom to 3.05 then 3.20 market cap 346M leaves room for expansion while story heats
0 · Reply
BarbaraKeller
BarbaraKeller Oct. 7 at 7:43 PM
$TAOX NXXT tape showed uptick dominance near 70 percent into close T and S steady green prints of 10k to 20k size those programs usually target round numbers next likely magnet 3.00 followed by 3.20
0 · Reply
Orangotango
Orangotango Oct. 7 at 7:26 PM
$TAOX
0 · Reply
Latest News on TAOX
TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 17 days ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 4 weeks ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 6 weeks ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 3 months ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 3 months ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 3 months ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 4 months ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 10 months ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 1 year ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 1 year ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Dec 9, 2022, 11:50 AM EST - 3 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 3 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 16, 2021, 11:07 PM EST - 4 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Oct 5, 2021, 9:14 AM EDT - 4 years ago

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 4 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Jul 26, 2021, 1:47 PM EDT - 4 years ago

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 4 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 21, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 14, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Jul 7, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

TaoistTrader
TaoistTrader Oct. 9 at 5:56 PM
$TAOX giving back all them gains 🤔
0 · Reply
SnoopyPotter
SnoopyPotter Oct. 9 at 12:45 PM
$TAOX $TAO.X to $1,500? $TAOX could hit $36+ (base case)! With 42K+ $TAO.X staked. If $TAO.X reaches $3K, we’re talking about 10x potential from $7.75! Earnings Dec 3 for staking updates. What's your price target? #Bittensor #Crypto #BullRun Not advice, DYOR
0 · Reply
IldijanaMM
IldijanaMM Oct. 9 at 12:35 PM
$QCLS $TAO.X $TAOX How dose your all in play going JJ?
1 · Reply
JJBurch
JJBurch Oct. 9 at 10:38 AM
$QCLS just waiting on that ONE or and likely about $TAO.X ( $TAOX ) and this will join the 1000%+ club The best part of waiting is the ability to continue to accumulate more shares I thank god (my hard work in life) for the ability to do so. I’m so excited for this one it’s nearly ridiculous. Just absolutely SO EXCITED!! Let’s go @jaltucher LFG!!!
0 · Reply
SnoopyPotter
SnoopyPotter Oct. 8 at 8:21 PM
$TAOX Led by @jaltucher $TAOX acquired 29,899 $TAO.X tokens for $10M (~$334/token). Massive potential for 10x by EOY with $TAO.X halving in December. Oct 2: If you’re bullish on $TAO.X’s year-end targets, $TAOX is a must-watch. Halving catalysts are near!
1 · Reply
EndGame1
EndGame1 Oct. 8 at 1:12 PM
$TAOX Back to $8. $TAO is getting traction from many high profiles on twitter.
0 · Reply
EndGame1
EndGame1 Oct. 7 at 8:08 PM
$TAOX It was time for some profit taking. Think long term though for big reward.
0 · Reply
MelanieEllis
MelanieEllis Oct. 7 at 7:57 PM
$TAOX NXXT consolidation between 2.85 and 2.95 into the close looks like fuel into tomorrow break 2.95 and vroom to 3.05 then 3.20 market cap 346M leaves room for expansion while story heats
0 · Reply
BarbaraKeller
BarbaraKeller Oct. 7 at 7:43 PM
$TAOX NXXT tape showed uptick dominance near 70 percent into close T and S steady green prints of 10k to 20k size those programs usually target round numbers next likely magnet 3.00 followed by 3.20
0 · Reply
Orangotango
Orangotango Oct. 7 at 7:26 PM
$TAOX
0 · Reply
TaoistTrader
TaoistTrader Oct. 7 at 6:50 PM
$QCLS $TAOX $WRAP reminds me I should add some to wrap
1 · Reply
TaoistTrader
TaoistTrader Oct. 7 at 6:42 PM
$QCLS $TAOX I looked him up on Bloomberg Terminal and didn’t see QCLS. I did see he’s affiliated with $WRAP which I know James is an investor of
1 · Reply
TaoistTrader
TaoistTrader Oct. 7 at 6:41 PM
$TAOX decentralized AI is gonna be huge when Sam Altman Overlord wants to control what you think 🤔
0 · Reply
EndGame1
EndGame1 Oct. 7 at 3:52 PM
$TAOX Barry Silbert on X..."We’re seeing the best minds in crypto move to Bittensor $TAO Welcoming Greg and Jeff to the Yuma team, founders from the early Bitcoin days joining us to help scale decentralized intelligence."
0 · Reply
EndGame1
EndGame1 Oct. 7 at 3:17 PM
$DGXX $BLNE $TAOX Watch $IWM $244.09 for possible reversal. That was a daily gap up.
0 · Reply
JJBurch
JJBurch Oct. 7 at 1:33 PM
$TAOX I’m telling you This one has been skyrocketing and we know it’s connected to $QCLS QCLS is going 1000%+ very quickly I keep adding It’s almost ready. $QUBT $PLTR $AMD
1 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 7 at 11:52 AM
$TAOX
0 · Reply
knowthyself
knowthyself Oct. 7 at 9:07 AM
$QCLS $TAOX
0 · Reply
JJBurch
JJBurch Oct. 7 at 8:34 AM
$QCLS one should recognize that Bruce Bernstein is on the Boards of both QCLS AND. $TAOX This @jaltucher thing runs deep with insiders. All of them are now fully loaded up with warrants and RSUs and shares They’re all fully vested Let the news, and the games, begin!! Have fun everyone.
3 · Reply
TaoistTrader
TaoistTrader Oct. 6 at 6:14 PM
$TAOX looking good today 🤙🏻
1 · Reply
JJBurch
JJBurch Oct. 6 at 5:20 PM
$QCLS time to let loose $TAOX These are connected News is coming Prepare folks I mean it. Really really mean it
0 · Reply
EndGame1
EndGame1 Oct. 6 at 4:12 PM
$TAOX Hope long term longs held the dip. This has a long way to go.
0 · Reply